Higher diversity of anti-diabetic therapy is associated with lower risk of major adverse kidney events in diabetes
Eine höhere Vielfalt antidiabetischer Therapie ist mit einem geringeren Risiko für major adverse kidney events bei Diabetes assoziiert
World Journal of Diabetes · 15.11.2026 · 17 (11)
DOI: 10.4239/wjd.123922 ↗Auf einen Blick
Bei Menschen mit Diabetes war Kombinationstherapie mit einem geringeren Risiko für major adverse kidney events verbunden als Monotherapie.
Fragestellung
Ist eine höhere Vielfalt antidiabetischer Therapie bei Diabetes mit langfristig besseren renalen Ergebnissen verbunden als Monotherapie?
Methode
Beobachtungsstudie mit target-trial-Emulation in UK Biobank und Chongqing Diabetes Registry bei Personen mit Diabetes und HbA1c ≥ 7 %. Verglichen wurden Monotherapie und Kombinationstherapie.
Ergebnisse
In der UK Biobank wurden 3475 Paare identifiziert; über median 13.4 Jahre war das MAKE-Risiko unter Kombinationstherapie niedriger als unter Monotherapie (HR 0.65; 95 %-KI 0.46–0.92). In der CDR war das Risiko ebenfalls niedriger (HR 0.24; 95 %-KI 0.11–0.55).
Schlussfolgerung der Autor:innen
Jenseits der glykämischen Kontrolle ist eine größere Vielfalt antidiabetischer Therapie bei Diabetes mit einem geringeren Risiko für MAKE assoziiert.
Kernaussagen
- Kombinationstherapie war mit geringerem MAKE-Risiko verbunden.
- UKB: HR 0.65; 95 %-KI 0.46–0.92
- CDR: HR 0.24; 95 %-KI 0.11–0.55
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift World Journal of Diabetes, online erschienen am 15.11.2026. Verfasst von Shu-Ping Zhang und 15 weiteren Autor:innen. Die Arbeit nennt 29 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
BACKGROUND Diverse anti-diabetic combinations are widely indicated for uncontrolled hyperglycemia to avoid microvascular complications including kidney injury. Current studies on combination therapy’s long-term renal risk yield conflicting results, largely limited by inadequate confounder adjustment. We hypothesized combination anti-diabetic therapy reduces major adverse kidney events (MAKE) vs monotherapy in diabetic patients. AIM To investigate the association between the diversity of anti-diabetic therapy and long-term renal outcomes in patients with diabetes. METHODS We included participants with diabetes and glycated hemoglobin A1c ≥ 7% from the UK Biobank (UKB) and Chongqing Diabetes Registry (CDR). Using a target trial emulation design, we compared the effect of monotherapy vs combination therapy on MAKE (composite of end-stage renal disease and kidney disease death). Intention-to-treat and per-protocol analyses were conducted in UKB and CDR, respectively. RESULTS Propensity score matching identified 3475 monotherapy-combination therapy pairs in the UKB and 261-808 pairs in the CDR. Over median 13.4 years in UKB, combination therapy was associated with lower MAKE risk vs monotherapy (hazard ratio 0.65; 95% confidence interval: 0.46-0.92). In CDR, when compared with patients who maintained monotherapy, patients who maintained combination therapy had significantly lower risk of MAKE (hazard ratio 0.24; 95% confidence interval: 0.11-0.55) although their glycated hemoglobin A1c level was similar at baseline and during follow up. Sensitivity analyses excluding renoprotective medications showed consistent results. CONCLUSION Beyond glycemic control, a greater diversity of anti-diabetic therapy is associated with lower risk of MAKE in diabetic patients.
Zitieren
APA
Zhang, S., Huang, T., Zeng, Q., Luo, W., Xiong, Y., Peng, C., Lian, F., Cheng, Q., Wang, Z., Huang, W., Xu, Y., Li, Q., Yang, S., Chen, X., Hu, J., & Li, X. (2026). Higher diversity of anti-diabetic therapy is associated with lower risk of major adverse kidney events in diabetes. World Journal of Diabetes, 17(11). https://doi.org/10.4239/wjd.123922
Vancouver
Zhang S, Huang T, Zeng Q, Luo W, Xiong Y, Peng C, et al. Higher diversity of anti-diabetic therapy is associated with lower risk of major adverse kidney events in diabetes. World Journal of Diabetes. 2026;17(11). doi:10.4239/wjd.123922
BibTeX
@article{Zhang2026,
author = {Zhang, Shu-Ping and Huang, Ting-Ting and Zeng, Qing-Lian and Luo, Wen-Jin and Xiong, Yun-Jie and Peng, Chuan and Lian, Fei and Cheng, Qing-Feng and Wang, Zhi-Hong and Huang, Wei and Xu, Yong and Li, Qi-Fu and Yang, Shu-Min and Chen, Xiang-Jun and Hu, Jin-Bo and Li, Xi-Yue},
title = {Higher diversity of anti-diabetic therapy is associated with lower risk of major adverse kidney events in diabetes},
journal = {World Journal of Diabetes},
year = {2026},
volume = {17},
number = {11},
doi = {10.4239/wjd.123922}
}
EUVIMED